初代細胞市場：由来、電池タイプ、エンドユーザー別-2025～2030年の世界予測

初代細胞市場は、2023年に14億3,000万米ドルと評価され、2024年には16億米ドルに達すると予測され、CAGR 12.10%で成長し、2030年には31億8,000万米ドルに達すると予測されています。

初代細胞市場は、ライフサイエンスにおける細胞生理学や医薬品開発の研究に不可欠な役割を果たすことにより、大きく拡大しています。初代細胞は、生体組織から直接採取され、本来の機能や遺伝子を保持しているため、細胞株と比較して、より本格的な生物学研究に不可欠です。その必要性は、生体内の状態を模倣する関連性から、生物医療研究、創薬、組織工学に及んでいます。用途はがん研究、心臓血管研究、神経科学など多岐にわたり、エンドユーザーは研究機関、製薬会社、バイオテクノロジー企業が中心です。バイオテクノロジーの進歩、個別化医療への注目の高まり、細胞ベースの研究に対する政府資金の増加などが、この市場の成長に影響を与える主要要因です。急成長している再生医療セグメントは、初代細胞が新規治療候補を開発するための重要な要素となっており、大きなビジネス機会をもたらしています。しかし、細胞の分離や維持にかかる高いコストや、動物やヒト由来の細胞源に関する倫理的な懸念が市場成長の課題となっています。3D細胞培養やCRISPR遺伝子編集のような技術革新がブレークスルーをもたらし、研究者により費用対効果が高く効率的なツールを提供する可能性があります。競合を維持するために、企業がこれらのセグメントに投資することは有益であると考えられます。多施設共同研究や学術機関との提携は、リソースや知識をプールすることでいくつかの制限を克服するのに役立ち、その結果、現在のアプリケーションを拡大し、開発を促進することができます。技術革新の鍵となるセグメントの一つは、ばらつきを抑え、研究結果の再現性を高めることができる、標準化された手ごろなプライマリー細胞株の作成です。市場はダイナミックで競争が激しく、このセグメントでの成長と関連性を維持するために、企業は新しい科学的発見や技術の進歩に適応し続ける必要があります。

市場力学：急速に進化する初代細胞市場の主要市場洞察を公開

初代細胞市場は、需要と供給のダイナミックな相互作用によって変貌を遂げています。このような市場力学の進化を理解することで、企業は十分な情報に基づいた投資決定、戦略的意思決定、新たなビジネス機会の獲得を行うことができます。これらの動向を包括的に把握することで、企業は政治的、地理的、技術的、社会的、経済的な領域にわたる様々なリスクを軽減することができるとともに、消費者行動とそれが製造コストや購買動向に与える影響をより明確に理解することができます。

• 市場促進要因
  • 薬剤スクリーニングと細胞ベースのアッセイにおける受け入れの拡大
  • その他の既存の方法と比べた初代ヒト細胞の利点
  • モノクローナル抗体と個別化医療への関心の高まり
• 市場抑制要因
  • コンタミネーションなどの一般的な細胞培養の問題
• 市場機会
  • バイオテクノロジーとバイオ医薬品産業の拡大
  • 初代細胞を用いた生物医療研究の進展
• 市場課題
  • 細胞生物学研究セグメントにおける倫理的問題

ポーターのファイブフォース：初代細胞市場をナビゲートする戦略ツール

ポーターのファイブフォースフレームワークは、初代細胞市場の競合情勢を理解するための重要なツールです。ポーターのファイブフォースフレームワークは、企業の競合を評価し、戦略的機会を探るための明確な手法を記載しています。このフレームワークは、企業が市場内の勢力図を評価し、新規事業の収益性を判断するのに役立ちます。これら洞察により、企業は自社の強みを活かし、弱みに対処し、潜在的な課題を回避することで、より強靭な市場でのポジショニングを確保することができます。

PESTLE分析：初代細胞市場における外部からの影響の把握

外部マクロ環境要因は、初代細胞市場の業績力学を形成する上で極めて重要な役割を果たします。政治的、経済的、社会的、技術的、法的、環境的要因の分析は、これらの影響をナビゲートするために必要な情報を記載しています。PESTLE要因を調査することで、企業は潜在的なリスクと機会をよりよく理解することができます。この分析により、企業は規制、消費者の嗜好、経済動向の変化を予測し、先を見越した積極的な意思決定を行う準備ができます。

市場シェア分析：初代細胞市場における競合情勢の把握

初代細胞市場の詳細な市場シェア分析により、ベンダーの業績を包括的に評価することができます。企業は、収益、顧客ベース、成長率などの主要指標を比較することで、競争上のポジショニングを明らかにすることができます。この分析により、市場の集中、セグメント化、統合の動向が明らかになり、ベンダーは競争が激化する中で自社の地位を高める戦略的意思決定を行うために必要な知見を得ることができます。

FPNVポジショニングマトリックス：初代細胞市場におけるベンダーのパフォーマンス評価

FPNVポジショニングマトリックスは、初代細胞市場においてベンダーを評価するための重要なツールです。このマトリックスにより、ビジネス組織はベンダーのビジネス戦略と製品満足度に基づき評価することで、目標に沿った十分な情報に基づいた意思決定を行うことができます。4つの象限によってベンダーを明確かつ正確にセグメント化し、戦略目標に最適なパートナーやソリューションを特定することができます。

戦略分析と推奨：初代細胞市場における成功への道筋を描く

初代細胞市場の戦略分析は、世界市場でのプレゼンス強化を目指す企業にとって不可欠です。主要なリソース、能力、業績指標を見直すことで、企業は成長機会を特定し、改善に取り組むことができます。このアプローチにより、競合情勢における課題を克服し、新たなビジネス機会を活かして長期的な成功を収めるための体制を整えることができます。

本レポートでは、主要な注目セグメントを網羅した市場の包括的な分析を提供しています。

1.市場の浸透度：現在の市場環境の詳細なレビュー、主要企業による広範なデータ、市場でのリーチと全体的な影響力を評価します。

2.市場の開拓度：新興市場における成長機会を特定し、既存セグメントにおける拡大可能性を評価し、将来の成長に向けた戦略的ロードマップを記載しています。

3.市場の多様化：最近の製品発売、未開拓の地域、産業の主要な進歩、市場を形成する戦略的投資を分析します。

4.競合の評価と情報：競合情勢を徹底的に分析し、市場シェア、事業戦略、製品ポートフォリオ、認証、規制当局の承認、特許動向、主要企業の技術進歩などを検証します。

5.製品開発とイノベーション：将来の市場成長を促進すると期待される最先端技術、研究開発活動、製品イノベーションをハイライトしています。

また、利害関係者が十分な情報を得た上で意思決定できるよう、重要な質問にも答えています。

1.現在の市場規模と今後の成長予測は？

2.最高の投資機会を提供する製品、地域はどこか？

3.市場を形成する主要技術動向と規制の影響とは？

4.主要ベンダーの市場シェアと競合ポジションは？

5.ベンダーの市場参入・撤退戦略の原動力となる収益源と戦略的機会は何か？

目次

第1章 序文

第2章 調査手法

第3章 エグゼクティブサマリー

第4章 市場概要

第5章 市場洞察

• 市場力学
  • 促進要因
    • 薬剤スクリーニングと細胞ベースのアッセイの普及
    • 既存の方法と比較したヒト初代細胞の利点
    • モノクローナル抗体と個別化医療への注目が高まる
  • 抑制要因
    • 汚染などの一般的な細胞培養の問題
  • 機会
    • バイオテクノロジーとバイオ医薬品産業の拡大
    • 初代細胞を使用した生物医学研究の進歩
  • 課題
    • 細胞生物学研究セグメントにおける倫理的問題
• 市場セグメンテーション分析
  • 由来：人間の細胞反応を正確に表現するための人間の初代細胞に対する好みの高まり
  • 細胞タイプ：医薬品開発と毒性検査における皮膚細胞の採用増加
  • エンドユーザー：実験中に正確な結果を保証するために、ライフサイエンス企業で初代細胞の使用が急増
• ポーターのファイブフォース分析
• PESTEL分析
  • 政治
  • 経済
  • 社会
  • 技術
  • 法律
  • 環境

第6章 初代細胞市場：由来別

• イントロダクション
• 動物
• ヒト

第7章 初代細胞市場：細胞タイプ別

• イントロダクション
• 皮膚細胞
• 消化管細胞
• 心臓細胞
• 造血細胞
• 肝細胞
  • 凍結保存肝細胞
  • 新鮮肝細胞
• 肺細胞
• 筋骨格細胞
• 腎細胞

第8章 初代細胞市場：エンドユーザー別

• イントロダクション
• ライフサイエンス企業
• 研究機関

第9章 南北アメリカの初代細胞市場

• イントロダクション
• アルゼンチン
• ブラジル
• カナダ
• メキシコ
• 米国

第10章 アジア太平洋の初代細胞市場

• イントロダクション
• オーストラリア
• 中国
• インド
• インドネシア
• 日本
• マレーシア
• フィリピン
• シンガポール
• 韓国
• 台湾
• タイ
• ベトナム

第11章 欧州・中東・アフリカの初代細胞市場

• イントロダクション
• デンマーク
• エジプト
• フィンランド
• フランス
• ドイツ
• イスラエル
• イタリア
• オランダ
• ナイジェリア
• ノルウェー
• ポーランド
• カタール
• ロシア
• サウジアラビア
• 南アフリカ
• スペイン
• スウェーデン
• スイス
• トルコ
• アラブ首長国連邦
• 英国

第12章 競合情勢

• 市場シェア分析、2023年
• FPNVポジショニングマトリックス、2023年
• 競合シナリオ分析
  • CN BioとLifeNet Health LifeSciencesが提携し、微小生理学システム向けの検証済み初代ヒト細胞を供給
  • AnaBiosがCell Systemsを買収し、創薬のためのヒト細胞ポートフォリオを拡大
  • Human Cell Designが、1型と2型糖尿病調査における新たな発見を可能にする先進的なヒトベータ細胞モデル、Endoc-BH5を発売
• 戦略分析と提言

企業一覧

• Biopredic International
• Corning Incorporated
• Danaher Corporation
• FUJIFILM Irvine Scientific, Inc.
• Lonza AG
• PromoCell GmbH
• Reachbio LLC
• Sciencell Research Laboratories, Inc.
• Sekisui Xenotech, LLC
• Stem Cell Technologies, Inc.
• StemExpress, LLC
• The Bio Convergence Company
• The Merck Group
• Thermo Fisher Scientific, Inc.
• Zenbio, Inc.

LIST OF FIGURES

• FIGURE 1. PRIMARY CELLS MARKET RESEARCH PROCESS
• FIGURE 2. PRIMARY CELLS MARKET SIZE, 2023 VS 2030
• FIGURE 3. GLOBAL PRIMARY CELLS MARKET SIZE, 2018-2030 (USD MILLION)
• FIGURE 4. GLOBAL PRIMARY CELLS MARKET SIZE, BY REGION, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 5. GLOBAL PRIMARY CELLS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 6. GLOBAL PRIMARY CELLS MARKET SIZE, BY ORIGIN, 2023 VS 2030 (%)
• FIGURE 7. GLOBAL PRIMARY CELLS MARKET SIZE, BY ORIGIN, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 8. GLOBAL PRIMARY CELLS MARKET SIZE, BY CELL TYPE, 2023 VS 2030 (%)
• FIGURE 9. GLOBAL PRIMARY CELLS MARKET SIZE, BY CELL TYPE, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 10. GLOBAL PRIMARY CELLS MARKET SIZE, BY END-USER, 2023 VS 2030 (%)
• FIGURE 11. GLOBAL PRIMARY CELLS MARKET SIZE, BY END-USER, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 12. AMERICAS PRIMARY CELLS MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
• FIGURE 13. AMERICAS PRIMARY CELLS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 14. UNITED STATES PRIMARY CELLS MARKET SIZE, BY STATE, 2023 VS 2030 (%)
• FIGURE 15. UNITED STATES PRIMARY CELLS MARKET SIZE, BY STATE, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 16. ASIA-PACIFIC PRIMARY CELLS MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
• FIGURE 17. ASIA-PACIFIC PRIMARY CELLS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 18. EUROPE, MIDDLE EAST & AFRICA PRIMARY CELLS MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
• FIGURE 19. EUROPE, MIDDLE EAST & AFRICA PRIMARY CELLS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 20. PRIMARY CELLS MARKET SHARE, BY KEY PLAYER, 2023
• FIGURE 21. PRIMARY CELLS MARKET, FPNV POSITIONING MATRIX, 2023

LIST OF TABLES

• TABLE 1. PRIMARY CELLS MARKET SEGMENTATION & COVERAGE
• TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2023
• TABLE 3. GLOBAL PRIMARY CELLS MARKET SIZE, 2018-2030 (USD MILLION)
• TABLE 4. GLOBAL PRIMARY CELLS MARKET SIZE, BY REGION, 2018-2030 (USD MILLION)
• TABLE 5. GLOBAL PRIMARY CELLS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
• TABLE 6. PRIMARY CELLS MARKET DYNAMICS
• TABLE 7. GLOBAL PRIMARY CELLS MARKET SIZE, BY ORIGIN, 2018-2030 (USD MILLION)
• TABLE 8. GLOBAL PRIMARY CELLS MARKET SIZE, BY ANIMAL PRIMARY CELLS, BY REGION, 2018-2030 (USD MILLION)
• TABLE 9. GLOBAL PRIMARY CELLS MARKET SIZE, BY HUMAN PRIMARY CELLS, BY REGION, 2018-2030 (USD MILLION)
• TABLE 10. GLOBAL PRIMARY CELLS MARKET SIZE, BY CELL TYPE, 2018-2030 (USD MILLION)
• TABLE 11. GLOBAL PRIMARY CELLS MARKET SIZE, BY DERMATOCYTES, BY REGION, 2018-2030 (USD MILLION)
• TABLE 12. GLOBAL PRIMARY CELLS MARKET SIZE, BY GASTROINTESTINAL CELLS, BY REGION, 2018-2030 (USD MILLION)
• TABLE 13. GLOBAL PRIMARY CELLS MARKET SIZE, BY HEART CELLS, BY REGION, 2018-2030 (USD MILLION)
• TABLE 14. GLOBAL PRIMARY CELLS MARKET SIZE, BY HEMATOPOIETIC CELLS, BY REGION, 2018-2030 (USD MILLION)
• TABLE 15. GLOBAL PRIMARY CELLS MARKET SIZE, BY HEPATOCYTES, BY REGION, 2018-2030 (USD MILLION)
• TABLE 16. GLOBAL PRIMARY CELLS MARKET SIZE, BY CRYOPRESERVED HEPATOCYTES, BY REGION, 2018-2030 (USD MILLION)
• TABLE 17. GLOBAL PRIMARY CELLS MARKET SIZE, BY FRESH HEPATOCYTES, BY REGION, 2018-2030 (USD MILLION)
• TABLE 18. GLOBAL PRIMARY CELLS MARKET SIZE, BY HEPATOCYTES, 2018-2030 (USD MILLION)
• TABLE 19. GLOBAL PRIMARY CELLS MARKET SIZE, BY LUNG CELLS, BY REGION, 2018-2030 (USD MILLION)
• TABLE 20. GLOBAL PRIMARY CELLS MARKET SIZE, BY MUSCULOSKELETAL CELLS, BY REGION, 2018-2030 (USD MILLION)
• TABLE 21. GLOBAL PRIMARY CELLS MARKET SIZE, BY RENAL CELLS, BY REGION, 2018-2030 (USD MILLION)
• TABLE 22. GLOBAL PRIMARY CELLS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 23. GLOBAL PRIMARY CELLS MARKET SIZE, BY LIFE SCIENCE COMPANIES, BY REGION, 2018-2030 (USD MILLION)
• TABLE 24. GLOBAL PRIMARY CELLS MARKET SIZE, BY RESEARCH INSTITUTES, BY REGION, 2018-2030 (USD MILLION)
• TABLE 25. AMERICAS PRIMARY CELLS MARKET SIZE, BY ORIGIN, 2018-2030 (USD MILLION)
• TABLE 26. AMERICAS PRIMARY CELLS MARKET SIZE, BY CELL TYPE, 2018-2030 (USD MILLION)
• TABLE 27. AMERICAS PRIMARY CELLS MARKET SIZE, BY HEPATOCYTES, 2018-2030 (USD MILLION)
• TABLE 28. AMERICAS PRIMARY CELLS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 29. AMERICAS PRIMARY CELLS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
• TABLE 30. ARGENTINA PRIMARY CELLS MARKET SIZE, BY ORIGIN, 2018-2030 (USD MILLION)
• TABLE 31. ARGENTINA PRIMARY CELLS MARKET SIZE, BY CELL TYPE, 2018-2030 (USD MILLION)
• TABLE 32. ARGENTINA PRIMARY CELLS MARKET SIZE, BY HEPATOCYTES, 2018-2030 (USD MILLION)
• TABLE 33. ARGENTINA PRIMARY CELLS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 34. BRAZIL PRIMARY CELLS MARKET SIZE, BY ORIGIN, 2018-2030 (USD MILLION)
• TABLE 35. BRAZIL PRIMARY CELLS MARKET SIZE, BY CELL TYPE, 2018-2030 (USD MILLION)
• TABLE 36. BRAZIL PRIMARY CELLS MARKET SIZE, BY HEPATOCYTES, 2018-2030 (USD MILLION)
• TABLE 37. BRAZIL PRIMARY CELLS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 38. CANADA PRIMARY CELLS MARKET SIZE, BY ORIGIN, 2018-2030 (USD MILLION)
• TABLE 39. CANADA PRIMARY CELLS MARKET SIZE, BY CELL TYPE, 2018-2030 (USD MILLION)
• TABLE 40. CANADA PRIMARY CELLS MARKET SIZE, BY HEPATOCYTES, 2018-2030 (USD MILLION)
• TABLE 41. CANADA PRIMARY CELLS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 42. MEXICO PRIMARY CELLS MARKET SIZE, BY ORIGIN, 2018-2030 (USD MILLION)
• TABLE 43. MEXICO PRIMARY CELLS MARKET SIZE, BY CELL TYPE, 2018-2030 (USD MILLION)
• TABLE 44. MEXICO PRIMARY CELLS MARKET SIZE, BY HEPATOCYTES, 2018-2030 (USD MILLION)
• TABLE 45. MEXICO PRIMARY CELLS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 46. UNITED STATES PRIMARY CELLS MARKET SIZE, BY ORIGIN, 2018-2030 (USD MILLION)
• TABLE 47. UNITED STATES PRIMARY CELLS MARKET SIZE, BY CELL TYPE, 2018-2030 (USD MILLION)
• TABLE 48. UNITED STATES PRIMARY CELLS MARKET SIZE, BY HEPATOCYTES, 2018-2030 (USD MILLION)
• TABLE 49. UNITED STATES PRIMARY CELLS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 50. UNITED STATES PRIMARY CELLS MARKET SIZE, BY STATE, 2018-2030 (USD MILLION)
• TABLE 51. ASIA-PACIFIC PRIMARY CELLS MARKET SIZE, BY ORIGIN, 2018-2030 (USD MILLION)
• TABLE 52. ASIA-PACIFIC PRIMARY CELLS MARKET SIZE, BY CELL TYPE, 2018-2030 (USD MILLION)
• TABLE 53. ASIA-PACIFIC PRIMARY CELLS MARKET SIZE, BY HEPATOCYTES, 2018-2030 (USD MILLION)
• TABLE 54. ASIA-PACIFIC PRIMARY CELLS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 55. ASIA-PACIFIC PRIMARY CELLS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
• TABLE 56. AUSTRALIA PRIMARY CELLS MARKET SIZE, BY ORIGIN, 2018-2030 (USD MILLION)
• TABLE 57. AUSTRALIA PRIMARY CELLS MARKET SIZE, BY CELL TYPE, 2018-2030 (USD MILLION)
• TABLE 58. AUSTRALIA PRIMARY CELLS MARKET SIZE, BY HEPATOCYTES, 2018-2030 (USD MILLION)
• TABLE 59. AUSTRALIA PRIMARY CELLS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 60. CHINA PRIMARY CELLS MARKET SIZE, BY ORIGIN, 2018-2030 (USD MILLION)
• TABLE 61. CHINA PRIMARY CELLS MARKET SIZE, BY CELL TYPE, 2018-2030 (USD MILLION)
• TABLE 62. CHINA PRIMARY CELLS MARKET SIZE, BY HEPATOCYTES, 2018-2030 (USD MILLION)
• TABLE 63. CHINA PRIMARY CELLS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 64. INDIA PRIMARY CELLS MARKET SIZE, BY ORIGIN, 2018-2030 (USD MILLION)
• TABLE 65. INDIA PRIMARY CELLS MARKET SIZE, BY CELL TYPE, 2018-2030 (USD MILLION)
• TABLE 66. INDIA PRIMARY CELLS MARKET SIZE, BY HEPATOCYTES, 2018-2030 (USD MILLION)
• TABLE 67. INDIA PRIMARY CELLS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 68. INDONESIA PRIMARY CELLS MARKET SIZE, BY ORIGIN, 2018-2030 (USD MILLION)
• TABLE 69. INDONESIA PRIMARY CELLS MARKET SIZE, BY CELL TYPE, 2018-2030 (USD MILLION)
• TABLE 70. INDONESIA PRIMARY CELLS MARKET SIZE, BY HEPATOCYTES, 2018-2030 (USD MILLION)
• TABLE 71. INDONESIA PRIMARY CELLS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 72. JAPAN PRIMARY CELLS MARKET SIZE, BY ORIGIN, 2018-2030 (USD MILLION)
• TABLE 73. JAPAN PRIMARY CELLS MARKET SIZE, BY CELL TYPE, 2018-2030 (USD MILLION)
• TABLE 74. JAPAN PRIMARY CELLS MARKET SIZE, BY HEPATOCYTES, 2018-2030 (USD MILLION)
• TABLE 75. JAPAN PRIMARY CELLS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 76. MALAYSIA PRIMARY CELLS MARKET SIZE, BY ORIGIN, 2018-2030 (USD MILLION)
• TABLE 77. MALAYSIA PRIMARY CELLS MARKET SIZE, BY CELL TYPE, 2018-2030 (USD MILLION)
• TABLE 78. MALAYSIA PRIMARY CELLS MARKET SIZE, BY HEPATOCYTES, 2018-2030 (USD MILLION)
• TABLE 79. MALAYSIA PRIMARY CELLS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 80. PHILIPPINES PRIMARY CELLS MARKET SIZE, BY ORIGIN, 2018-2030 (USD MILLION)
• TABLE 81. PHILIPPINES PRIMARY CELLS MARKET SIZE, BY CELL TYPE, 2018-2030 (USD MILLION)
• TABLE 82. PHILIPPINES PRIMARY CELLS MARKET SIZE, BY HEPATOCYTES, 2018-2030 (USD MILLION)
• TABLE 83. PHILIPPINES PRIMARY CELLS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 84. SINGAPORE PRIMARY CELLS MARKET SIZE, BY ORIGIN, 2018-2030 (USD MILLION)
• TABLE 85. SINGAPORE PRIMARY CELLS MARKET SIZE, BY CELL TYPE, 2018-2030 (USD MILLION)
• TABLE 86. SINGAPORE PRIMARY CELLS MARKET SIZE, BY HEPATOCYTES, 2018-2030 (USD MILLION)
• TABLE 87. SINGAPORE PRIMARY CELLS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 88. SOUTH KOREA PRIMARY CELLS MARKET SIZE, BY ORIGIN, 2018-2030 (USD MILLION)
• TABLE 89. SOUTH KOREA PRIMARY CELLS MARKET SIZE, BY CELL TYPE, 2018-2030 (USD MILLION)
• TABLE 90. SOUTH KOREA PRIMARY CELLS MARKET SIZE, BY HEPATOCYTES, 2018-2030 (USD MILLION)
• TABLE 91. SOUTH KOREA PRIMARY CELLS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 92. TAIWAN PRIMARY CELLS MARKET SIZE, BY ORIGIN, 2018-2030 (USD MILLION)
• TABLE 93. TAIWAN PRIMARY CELLS MARKET SIZE, BY CELL TYPE, 2018-2030 (USD MILLION)
• TABLE 94. TAIWAN PRIMARY CELLS MARKET SIZE, BY HEPATOCYTES, 2018-2030 (USD MILLION)
• TABLE 95. TAIWAN PRIMARY CELLS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 96. THAILAND PRIMARY CELLS MARKET SIZE, BY ORIGIN, 2018-2030 (USD MILLION)
• TABLE 97. THAILAND PRIMARY CELLS MARKET SIZE, BY CELL TYPE, 2018-2030 (USD MILLION)
• TABLE 98. THAILAND PRIMARY CELLS MARKET SIZE, BY HEPATOCYTES, 2018-2030 (USD MILLION)
• TABLE 99. THAILAND PRIMARY CELLS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 100. VIETNAM PRIMARY CELLS MARKET SIZE, BY ORIGIN, 2018-2030 (USD MILLION)
• TABLE 101. VIETNAM PRIMARY CELLS MARKET SIZE, BY CELL TYPE, 2018-2030 (USD MILLION)
• TABLE 102. VIETNAM PRIMARY CELLS MARKET SIZE, BY HEPATOCYTES, 2018-2030 (USD MILLION)
• TABLE 103. VIETNAM PRIMARY CELLS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 104. EUROPE, MIDDLE EAST & AFRICA PRIMARY CELLS MARKET SIZE, BY ORIGIN, 2018-2030 (USD MILLION)
• TABLE 105. EUROPE, MIDDLE EAST & AFRICA PRIMARY CELLS MARKET SIZE, BY CELL TYPE, 2018-2030 (USD MILLION)
• TABLE 106. EUROPE, MIDDLE EAST & AFRICA PRIMARY CELLS MARKET SIZE, BY HEPATOCYTES, 2018-2030 (USD MILLION)
• TABLE 107. EUROPE, MIDDLE EAST & AFRICA PRIMARY CELLS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 108. EUROPE, MIDDLE EAST & AFRICA PRIMARY CELLS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
• TABLE 109. DENMARK PRIMARY CELLS MARKET SIZE, BY ORIGIN, 2018-2030 (USD MILLION)
• TABLE 110. DENMARK PRIMARY CELLS MARKET SIZE, BY CELL TYPE, 2018-2030 (USD MILLION)
• TABLE 111. DENMARK PRIMARY CELLS MARKET SIZE, BY HEPATOCYTES, 2018-2030 (USD MILLION)
• TABLE 112. DENMARK PRIMARY CELLS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 113. EGYPT PRIMARY CELLS MARKET SIZE, BY ORIGIN, 2018-2030 (USD MILLION)
• TABLE 114. EGYPT PRIMARY CELLS MARKET SIZE, BY CELL TYPE, 2018-2030 (USD MILLION)
• TABLE 115. EGYPT PRIMARY CELLS MARKET SIZE, BY HEPATOCYTES, 2018-2030 (USD MILLION)
• TABLE 116. EGYPT PRIMARY CELLS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 117. FINLAND PRIMARY CELLS MARKET SIZE, BY ORIGIN, 2018-2030 (USD MILLION)
• TABLE 118. FINLAND PRIMARY CELLS MARKET SIZE, BY CELL TYPE, 2018-2030 (USD MILLION)
• TABLE 119. FINLAND PRIMARY CELLS MARKET SIZE, BY HEPATOCYTES, 2018-2030 (USD MILLION)
• TABLE 120. FINLAND PRIMARY CELLS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 121. FRANCE PRIMARY CELLS MARKET SIZE, BY ORIGIN, 2018-2030 (USD MILLION)
• TABLE 122. FRANCE PRIMARY CELLS MARKET SIZE, BY CELL TYPE, 2018-2030 (USD MILLION)
• TABLE 123. FRANCE PRIMARY CELLS MARKET SIZE, BY HEPATOCYTES, 2018-2030 (USD MILLION)
• TABLE 124. FRANCE PRIMARY CELLS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 125. GERMANY PRIMARY CELLS MARKET SIZE, BY ORIGIN, 2018-2030 (USD MILLION)
• TABLE 126. GERMANY PRIMARY CELLS MARKET SIZE, BY CELL TYPE, 2018-2030 (USD MILLION)
• TABLE 127. GERMANY PRIMARY CELLS MARKET SIZE, BY HEPATOCYTES, 2018-2030 (USD MILLION)
• TABLE 128. GERMANY PRIMARY CELLS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 129. ISRAEL PRIMARY CELLS MARKET SIZE, BY ORIGIN, 2018-2030 (USD MILLION)
• TABLE 130. ISRAEL PRIMARY CELLS MARKET SIZE, BY CELL TYPE, 2018-2030 (USD MILLION)
• TABLE 131. ISRAEL PRIMARY CELLS MARKET SIZE, BY HEPATOCYTES, 2018-2030 (USD MILLION)
• TABLE 132. ISRAEL PRIMARY CELLS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 133. ITALY PRIMARY CELLS MARKET SIZE, BY ORIGIN, 2018-2030 (USD MILLION)
• TABLE 134. ITALY PRIMARY CELLS MARKET SIZE, BY CELL TYPE, 2018-2030 (USD MILLION)
• TABLE 135. ITALY PRIMARY CELLS MARKET SIZE, BY HEPATOCYTES, 2018-2030 (USD MILLION)
• TABLE 136. ITALY PRIMARY CELLS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 137. NETHERLANDS PRIMARY CELLS MARKET SIZE, BY ORIGIN, 2018-2030 (USD MILLION)
• TABLE 138. NETHERLANDS PRIMARY CELLS MARKET SIZE, BY CELL TYPE, 2018-2030 (USD MILLION)
• TABLE 139. NETHERLANDS PRIMARY CELLS MARKET SIZE, BY HEPATOCYTES, 2018-2030 (USD MILLION)
• TABLE 140. NETHERLANDS PRIMARY CELLS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 141. NIGERIA PRIMARY CELLS MARKET SIZE, BY ORIGIN, 2018-2030 (USD MILLION)
• TABLE 142. NIGERIA PRIMARY CELLS MARKET SIZE, BY CELL TYPE, 2018-2030 (USD MILLION)
• TABLE 143. NIGERIA PRIMARY CELLS MARKET SIZE, BY HEPATOCYTES, 2018-2030 (USD MILLION)
• TABLE 144. NIGERIA PRIMARY CELLS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 145. NORWAY PRIMARY CELLS MARKET SIZE, BY ORIGIN, 2018-2030 (USD MILLION)
• TABLE 146. NORWAY PRIMARY CELLS MARKET SIZE, BY CELL TYPE, 2018-2030 (USD MILLION)
• TABLE 147. NORWAY PRIMARY CELLS MARKET SIZE, BY HEPATOCYTES, 2018-2030 (USD MILLION)
• TABLE 148. NORWAY PRIMARY CELLS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 149. POLAND PRIMARY CELLS MARKET SIZE, BY ORIGIN, 2018-2030 (USD MILLION)
• TABLE 150. POLAND PRIMARY CELLS MARKET SIZE, BY CELL TYPE, 2018-2030 (USD MILLION)
• TABLE 151. POLAND PRIMARY CELLS MARKET SIZE, BY HEPATOCYTES, 2018-2030 (USD MILLION)
• TABLE 152. POLAND PRIMARY CELLS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 153. QATAR PRIMARY CELLS MARKET SIZE, BY ORIGIN, 2018-2030 (USD MILLION)
• TABLE 154. QATAR PRIMARY CELLS MARKET SIZE, BY CELL TYPE, 2018-2030 (USD MILLION)
• TABLE 155. QATAR PRIMARY CELLS MARKET SIZE, BY HEPATOCYTES, 2018-2030 (USD MILLION)
• TABLE 156. QATAR PRIMARY CELLS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 157. RUSSIA PRIMARY CELLS MARKET SIZE, BY ORIGIN, 2018-2030 (USD MILLION)
• TABLE 158. RUSSIA PRIMARY CELLS MARKET SIZE, BY CELL TYPE, 2018-2030 (USD MILLION)
• TABLE 159. RUSSIA PRIMARY CELLS MARKET SIZE, BY HEPATOCYTES, 2018-2030 (USD MILLION)
• TABLE 160. RUSSIA PRIMARY CELLS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 161. SAUDI ARABIA PRIMARY CELLS MARKET SIZE, BY ORIGIN, 2018-2030 (USD MILLION)
• TABLE 162. SAUDI ARABIA PRIMARY CELLS MARKET SIZE, BY CELL TYPE, 2018-2030 (USD MILLION)
• TABLE 163. SAUDI ARABIA PRIMARY CELLS MARKET SIZE, BY HEPATOCYTES, 2018-2030 (USD MILLION)
• TABLE 164. SAUDI ARABIA PRIMARY CELLS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 165. SOUTH AFRICA PRIMARY CELLS MARKET SIZE, BY ORIGIN, 2018-2030 (USD MILLION)
• TABLE 166. SOUTH AFRICA PRIMARY CELLS MARKET SIZE, BY CELL TYPE, 2018-2030 (USD MILLION)
• TABLE 167. SOUTH AFRICA PRIMARY CELLS MARKET SIZE, BY HEPATOCYTES, 2018-2030 (USD MILLION)
• TABLE 168. SOUTH AFRICA PRIMARY CELLS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 169. SPAIN PRIMARY CELLS MARKET SIZE, BY ORIGIN, 2018-2030 (USD MILLION)
• TABLE 170. SPAIN PRIMARY CELLS MARKET SIZE, BY CELL TYPE, 2018-2030 (USD MILLION)
• TABLE 171. SPAIN PRIMARY CELLS MARKET SIZE, BY HEPATOCYTES, 2018-2030 (USD MILLION)
• TABLE 172. SPAIN PRIMARY CELLS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 173. SWEDEN PRIMARY CELLS MARKET SIZE, BY ORIGIN, 2018-2030 (USD MILLION)
• TABLE 174. SWEDEN PRIMARY CELLS MARKET SIZE, BY CELL TYPE, 2018-2030 (USD MILLION)
• TABLE 175. SWEDEN PRIMARY CELLS MARKET SIZE, BY HEPATOCYTES, 2018-2030 (USD MILLION)
• TABLE 176. SWEDEN PRIMARY CELLS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 177. SWITZERLAND PRIMARY CELLS MARKET SIZE, BY ORIGIN, 2018-2030 (USD MILLION)
• TABLE 178. SWITZERLAND PRIMARY CELLS MARKET SIZE, BY CELL TYPE, 2018-2030 (USD MILLION)
• TABLE 179. SWITZERLAND PRIMARY CELLS MARKET SIZE, BY HEPATOCYTES, 2018-2030 (USD MILLION)
• TABLE 180. SWITZERLAND PRIMARY CELLS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 181. TURKEY PRIMARY CELLS MARKET SIZE, BY ORIGIN, 2018-2030 (USD MILLION)
• TABLE 182. TURKEY PRIMARY CELLS MARKET SIZE, BY CELL TYPE, 2018-2030 (USD MILLION)
• TABLE 183. TURKEY PRIMARY CELLS MARKET SIZE, BY HEPATOCYTES, 2018-2030 (USD MILLION)
• TABLE 184. TURKEY PRIMARY CELLS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 185. UNITED ARAB EMIRATES PRIMARY CELLS MARKET SIZE, BY ORIGIN, 2018-2030 (USD MILLION)
• TABLE 186. UNITED ARAB EMIRATES PRIMARY CELLS MARKET SIZE, BY CELL TYPE, 2018-2030 (USD MILLION)
• TABLE 187. UNITED ARAB EMIRATES PRIMARY CELLS MARKET SIZE, BY HEPATOCYTES, 2018-2030 (USD MILLION)
• TABLE 188. UNITED ARAB EMIRATES PRIMARY CELLS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 189. UNITED KINGDOM PRIMARY CELLS MARKET SIZE, BY ORIGIN, 2018-2030 (USD MILLION)
• TABLE 190. UNITED KINGDOM PRIMARY CELLS MARKET SIZE, BY CELL TYPE, 2018-2030 (USD MILLION)
• TABLE 191. UNITED KINGDOM PRIMARY CELLS MARKET SIZE, BY HEPATOCYTES, 2018-2030 (USD MILLION)
• TABLE 192. UNITED KINGDOM PRIMARY CELLS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 193. PRIMARY CELLS MARKET SHARE, BY KEY PLAYER, 2023
• TABLE 194. PRIMARY CELLS MARKET, FPNV POSITIONING MATRIX, 2023

The Primary Cells Market was valued at USD 1.43 billion in 2023, expected to reach USD 1.60 billion in 2024, and is projected to grow at a CAGR of 12.10%, to USD 3.18 billion by 2030.

The market for primary cells is expanding significantly, driven by their essential role in life sciences for studying cellular physiology and drug development. Primary cells are directly obtained from living tissues, retaining native functions and genetics, which makes them indispensable for more authentic biological research compared to cell lines. Their necessity spans across biomedical research, drug discovery, and tissue engineering due to their relevance in mimicking in vivo conditions. Applications are extensive including cancer research, cardiovascular studies, and neuroscience, with end-users predominantly comprising research institutes, pharmaceutical companies, and biotechnology firms. Key growth influencers in the primary cells market include advancements in biotechnology, a heightened focus on personalized medicine, and increasing government funding for cell-based research. The burgeoning field of regenerative medicine presents substantial opportunities, with primary cells serving as a crucial component for developing novel therapeutic candidates. However, market growth is challenged by the high costs of cell isolation and maintenance and the ethical concerns regarding animal and human-derived cell sources. Technological innovations such as 3D cell cultures and CRISPR gene editing could provide breakthroughs, offering more cost-effective and efficient tools for researchers. It would be beneficial for companies to invest in these areas to stay competitive. Multi-center collaborations and partnerships with academic institutions can help overcome some limitations by pooling resources and knowledge, thus expanding the current applications and expediting development. One of the key areas for innovation is in creating standardized and affordable primary cell lines that can reduce variability and enhance reproducibility of research outcomes. The market is dynamic and competitive, requiring businesses to stay adaptive to new scientific discoveries and technological advancements to maintain growth and relevance in the field.

Market Dynamics: Unveiling Key Market Insights in the Rapidly Evolving Primary Cells Market

The Primary Cells Market is undergoing transformative changes driven by a dynamic interplay of supply and demand factors. Understanding these evolving market dynamics prepares business organizations to make informed investment decisions, refine strategic decisions, and seize new opportunities. By gaining a comprehensive view of these trends, business organizations can mitigate various risks across political, geographic, technical, social, and economic domains while also gaining a clearer understanding of consumer behavior and its impact on manufacturing costs and purchasing trends.

• Market Drivers
  • Growing acceptance in drug screening and cell based assays
  • Advantages of primary human cells over other existing methods
  • Growing focus on monoclonal antibodies and personalized medicine
• Market Restraints
  • Common cell culture problems such as contamination
• Market Opportunities
  • Expanding biotechnology and biopharmaceutical industries
  • Advancements in biomedical research using primary cells
• Market Challenges
  • Ethical issues in cell biology research field

Porter's Five Forces: A Strategic Tool for Navigating the Primary Cells Market

Porter's five forces framework is a critical tool for understanding the competitive landscape of the Primary Cells Market. It offers business organizations with a clear methodology for evaluating their competitive positioning and exploring strategic opportunities. This framework helps businesses assess the power dynamics within the market and determine the profitability of new ventures. With these insights, business organizations can leverage their strengths, address weaknesses, and avoid potential challenges, ensuring a more resilient market positioning.

PESTLE Analysis: Navigating External Influences in the Primary Cells Market

External macro-environmental factors play a pivotal role in shaping the performance dynamics of the Primary Cells Market. Political, Economic, Social, Technological, Legal, and Environmental factors analysis provides the necessary information to navigate these influences. By examining PESTLE factors, businesses can better understand potential risks and opportunities. This analysis enables business organizations to anticipate changes in regulations, consumer preferences, and economic trends, ensuring they are prepared to make proactive, forward-thinking decisions.

Market Share Analysis: Understanding the Competitive Landscape in the Primary Cells Market

A detailed market share analysis in the Primary Cells Market provides a comprehensive assessment of vendors' performance. Companies can identify their competitive positioning by comparing key metrics, including revenue, customer base, and growth rates. This analysis highlights market concentration, fragmentation, and trends in consolidation, offering vendors the insights required to make strategic decisions that enhance their position in an increasingly competitive landscape.

FPNV Positioning Matrix: Evaluating Vendors' Performance in the Primary Cells Market

The Forefront, Pathfinder, Niche, Vital (FPNV) Positioning Matrix is a critical tool for evaluating vendors within the Primary Cells Market. This matrix enables business organizations to make well-informed decisions that align with their goals by assessing vendors based on their business strategy and product satisfaction. The four quadrants provide a clear and precise segmentation of vendors, helping users identify the right partners and solutions that best fit their strategic objectives.

Strategy Analysis & Recommendation: Charting a Path to Success in the Primary Cells Market

A strategic analysis of the Primary Cells Market is essential for businesses looking to strengthen their global market presence. By reviewing key resources, capabilities, and performance indicators, business organizations can identify growth opportunities and work toward improvement. This approach helps businesses navigate challenges in the competitive landscape and ensures they are well-positioned to capitalize on newer opportunities and drive long-term success.

Key Company Profiles

The report delves into recent significant developments in the Primary Cells Market, highlighting leading vendors and their innovative profiles. These include Biopredic International, Corning Incorporated, Danaher Corporation, FUJIFILM Irvine Scientific, Inc., Lonza AG, PromoCell GmbH, Reachbio LLC, Sciencell Research Laboratories, Inc., Sekisui Xenotech, LLC, Stem Cell Technologies, Inc., StemExpress, LLC, The Bio Convergence Company, The Merck Group, Thermo Fisher Scientific, Inc., and Zenbio, Inc..

Market Segmentation & Coverage

This research report categorizes the Primary Cells Market to forecast the revenues and analyze trends in each of the following sub-markets:

• Based on Origin, market is studied across Animal Primary Cells and Human Primary Cells.
• Based on Cell Type, market is studied across Dermatocytes, Gastrointestinal Cells, Heart Cells, Hematopoietic Cells, Hepatocytes, Lung Cells, Musculoskeletal Cells, and Renal Cells. The Hepatocytes is further studied across Cryopreserved Hepatocytes and Fresh Hepatocytes.
• Based on End-User, market is studied across Life Science Companies and Research Institutes.
• Based on Region, market is studied across Americas, Asia-Pacific, and Europe, Middle East & Africa. The Americas is further studied across Argentina, Brazil, Canada, Mexico, and United States. The United States is further studied across California, Florida, Illinois, New York, Ohio, Pennsylvania, and Texas. The Asia-Pacific is further studied across Australia, China, India, Indonesia, Japan, Malaysia, Philippines, Singapore, South Korea, Taiwan, Thailand, and Vietnam. The Europe, Middle East & Africa is further studied across Denmark, Egypt, Finland, France, Germany, Israel, Italy, Netherlands, Nigeria, Norway, Poland, Qatar, Russia, Saudi Arabia, South Africa, Spain, Sweden, Switzerland, Turkey, United Arab Emirates, and United Kingdom.

The report offers a comprehensive analysis of the market, covering key focus areas:

1. Market Penetration: A detailed review of the current market environment, including extensive data from top industry players, evaluating their market reach and overall influence.

2. Market Development: Identifies growth opportunities in emerging markets and assesses expansion potential in established sectors, providing a strategic roadmap for future growth.

3. Market Diversification: Analyzes recent product launches, untapped geographic regions, major industry advancements, and strategic investments reshaping the market.

4. Competitive Assessment & Intelligence: Provides a thorough analysis of the competitive landscape, examining market share, business strategies, product portfolios, certifications, regulatory approvals, patent trends, and technological advancements of key players.

5. Product Development & Innovation: Highlights cutting-edge technologies, R&D activities, and product innovations expected to drive future market growth.

The report also answers critical questions to aid stakeholders in making informed decisions:

1. What is the current market size, and what is the forecasted growth?

2. Which products, segments, and regions offer the best investment opportunities?

3. What are the key technology trends and regulatory influences shaping the market?

4. How do leading vendors rank in terms of market share and competitive positioning?

5. What revenue sources and strategic opportunities drive vendors' market entry or exit strategies?

Table of Contents

1. Preface

• 1.1. Objectives of the Study
• 1.2. Market Segmentation & Coverage
• 1.3. Years Considered for the Study
• 1.4. Currency & Pricing
• 1.5. Language
• 1.6. Stakeholders

2. Research Methodology

• 2.1. Define: Research Objective
• 2.2. Determine: Research Design
• 2.3. Prepare: Research Instrument
• 2.4. Collect: Data Source
• 2.5. Analyze: Data Interpretation
• 2.6. Formulate: Data Verification
• 2.7. Publish: Research Report
• 2.8. Repeat: Report Update

3. Executive Summary

4. Market Overview

5. Market Insights

• 5.1. Market Dynamics
  • 5.1.1. Drivers
    • 5.1.1.1. Growing acceptance in drug screening and cell based assays
    • 5.1.1.2. Advantages of primary human cells over other existing methods
    • 5.1.1.3. Growing focus on monoclonal antibodies and personalized medicine
  • 5.1.2. Restraints
    • 5.1.2.1. Common cell culture problems such as contamination
  • 5.1.3. Opportunities
    • 5.1.3.1. Expanding biotechnology and biopharmaceutical industries
    • 5.1.3.2. Advancements in biomedical research using primary cells
  • 5.1.4. Challenges
    • 5.1.4.1. Ethical issues in cell biology research field
• 5.2. Market Segmentation Analysis
  • 5.2.1. Origin: Increasing preference for human primary cells for accurate representations of human cellular responses
  • 5.2.2. Cell Type: Rising adoption of dermatocytes in drug development and toxicity testing
  • 5.2.3. End-User: Proliferating use of primary cells in life science companies to ensure accurate results during experimentation
• 5.3. Porter's Five Forces Analysis
  • 5.3.1. Threat of New Entrants
  • 5.3.2. Threat of Substitutes
  • 5.3.3. Bargaining Power of Customers
  • 5.3.4. Bargaining Power of Suppliers
  • 5.3.5. Industry Rivalry
• 5.4. PESTLE Analysis
  • 5.4.1. Political
  • 5.4.2. Economic
  • 5.4.3. Social
  • 5.4.4. Technological
  • 5.4.5. Legal
  • 5.4.6. Environmental

6. Primary Cells Market, by Origin

• 6.1. Introduction
• 6.2. Animal Primary Cells
• 6.3. Human Primary Cells

7. Primary Cells Market, by Cell Type

• 7.1. Introduction
• 7.2. Dermatocytes
• 7.3. Gastrointestinal Cells
• 7.4. Heart Cells
• 7.5. Hematopoietic Cells
• 7.6. Hepatocytes
  • 7.6.1. Cryopreserved Hepatocytes
  • 7.6.2. Fresh Hepatocytes
• 7.7. Lung Cells
• 7.8. Musculoskeletal Cells
• 7.9. Renal Cells

8. Primary Cells Market, by End-User

• 8.1. Introduction
• 8.2. Life Science Companies
• 8.3. Research Institutes

9. Americas Primary Cells Market

• 9.1. Introduction
• 9.2. Argentina
• 9.3. Brazil
• 9.4. Canada
• 9.5. Mexico
• 9.6. United States

10. Asia-Pacific Primary Cells Market

• 10.1. Introduction
• 10.2. Australia
• 10.3. China
• 10.4. India
• 10.5. Indonesia
• 10.6. Japan
• 10.7. Malaysia
• 10.8. Philippines
• 10.9. Singapore
• 10.10. South Korea
• 10.11. Taiwan
• 10.12. Thailand
• 10.13. Vietnam

11. Europe, Middle East & Africa Primary Cells Market

• 11.1. Introduction
• 11.2. Denmark
• 11.3. Egypt
• 11.4. Finland
• 11.5. France
• 11.6. Germany
• 11.7. Israel
• 11.8. Italy
• 11.9. Netherlands
• 11.10. Nigeria
• 11.11. Norway
• 11.12. Poland
• 11.13. Qatar
• 11.14. Russia
• 11.15. Saudi Arabia
• 11.16. South Africa
• 11.17. Spain
• 11.18. Sweden
• 11.19. Switzerland
• 11.20. Turkey
• 11.21. United Arab Emirates
• 11.22. United Kingdom

12. Competitive Landscape

• 12.1. Market Share Analysis, 2023
• 12.2. FPNV Positioning Matrix, 2023
• 12.3. Competitive Scenario Analysis
  • 12.3.1. CN Bio and LifeNet Health LifeSciences Partner to Supply Validated Primary Human Cells for Microphysiological Systems
  • 12.3.2. AnaBios Acquires Cell Systems, Expands Human Cell Portfolio for Drug Discovery
  • 12.3.3. Human Cell Design Launches Endoc-BH5, an Advanced Human Beta Cell Model enabling New Discoveries in Type 1 and 2 Diabetes Research
• 12.4. Strategy Analysis & Recommendation

Companies Mentioned

• 1. Biopredic International
• 2. Corning Incorporated
• 3. Danaher Corporation
• 4. FUJIFILM Irvine Scientific, Inc.
• 5. Lonza AG
• 6. PromoCell GmbH
• 7. Reachbio LLC
• 8. Sciencell Research Laboratories, Inc.
• 9. Sekisui Xenotech, LLC
• 10. Stem Cell Technologies, Inc.
• 11. StemExpress, LLC
• 12. The Bio Convergence Company
• 13. The Merck Group
• 14. Thermo Fisher Scientific, Inc.
• 15. Zenbio, Inc.